GlassScriptPhysician profile
Deirdre Callahan
NPI 1851935894
$9,766.20
in general payments reported to CMS, 2019-2025
16 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,044 · 2022: $1,815 · 2023: $2,346 · 2024: $2,560 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,795 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,795.23 |
| Education | $112.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,563.47 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $2,340.20 | 2021-2025 | |
| Alkermes, INC. | $1,341.04 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $762.94 | 2022-2024 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $496.91 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $423.44 | 2021-2024 | Caplyta |
| Indivior INC. | $402.09 | 2022-2025 | Sublocade, Perseris |
| Teva Pharmaceuticals USA, INC. | $289.79 | 2022-2024 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $247.79 | 2021-2024 | Fanapt, Hetlioz |
| Lundbeck LLC | $223.46 | 2021-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $181.11 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $170.76 | 2024-2025 | Cobenfy |
| Corium, LLC | $144.12 | 2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $74.09 | 2023-2025 | Trintellix |
| Axsome Therapeutics, INC. | $54.03 | 2023 | Auvelity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $50.96 | 2022-2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deirdre Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.